Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 225

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 225
---
 under the ATM agreement, net of commissions and offering costs of $16414,068 $— $474 $— $474 Exercise of common stock options87,704 $— 2,967 $— 2,967 Stock-based compensation— $— 8,785 $— 8,785 Net income (loss)— $— — (45,257)$(45,257)As of June 30, 202436,169,558 $3 $890,710 $(469,797)$420,916 

See notes to condensed consolidated financial statements.

7

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited)

SIX MONTHS ENDED JUNE 30,20252024CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)$117,755 $(88,371)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation expense714 583 Gain on disposal of fixed asset(14)— Stock-based compensation expense17,405 16,855 Non-cash lease expense1,179 685 Changes in operating assets and liabilities:Accounts receivable(13,074)139 Prepaid expenses and other current assets(557)(10,844)Other assets2,056 (26)Accounts payable651 1,636 Right-of-use assets and operating lease liabilities(907)(564)Deferred revenue925 — Current tax liability6,321 — Accrued expenses and other current liabilities(906)(4,454)Net cash provided by (used in) operating activities131,548 (84,361)CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of property and equipment(1,285)(1,256)Net cash used in investing activities(1,285)(1,256)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issuance of common stock, net of underwriting discounts— 151,340 Payment of issuance costs— (283)Proceeds from issuance of common stock under the ATM agreement, net of commissions— 629 Payment of issuance costs associated with issuance of common stock under the ATM agreement— (41)Proceeds from exercise of stock options21 8,688 Net cash provided by financing activities21